P-269 Lenvatinib in hepatocellular carcinoma: QoL surveys and radiological imaging markers predicting clinical outcome in patients with hepatocellular carcinoma treated with lenvatinib as first-line treatment (SULENVA-HCC)

Abstract

Hepatocarcinoma (HCC) is the most frequent primary liver neoplasm. In most cases, the diagnosis of HCC occurs in a context of non-operability or metastatic disease for which systemic treatment is indicated. In Italy, two drugs are indicated and reimbursed as first-line setting for HCC: sorafenib and lenvatinib. Lenvatinib is a small multitarget molecule that selectively inhibits kinase activities of pathway-related proangiogenic and oncogenic receptors. The efficacy of lenvatinib has been demonstrated in the randomized phase III REFLECT clinical trial.